Doxa AB
STO:DOXA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.01
3.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Doxa AB
PP&E Net
Doxa AB
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
D
|
Doxa AB
STO:DOXA
|
PP&E Net
kr6.3m
|
CAGR 3-Years
216%
|
CAGR 5-Years
99%
|
CAGR 10-Years
51%
|
|
O
|
OssDsign AB
STO:OSSD
|
PP&E Net
kr2.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Xvivo Perfusion AB
STO:XVIVO
|
PP&E Net
kr121.7m
|
CAGR 3-Years
78%
|
CAGR 5-Years
40%
|
CAGR 10-Years
65%
|
||
Bactiguard Holding AB
STO:BACTI B
|
PP&E Net
kr93.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
V
|
Vimian Group AB
STO:VIMIAN
|
PP&E Net
€35m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
PP&E Net
kr575k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
Doxa AB
Glance View
Doxa AB engages in the development, manufacture, and commercialization of bioceramic dental products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2014-04-07. The firm develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
See Also
What is Doxa AB's PP&E Net?
PP&E Net
6.3m
SEK
Based on the financial report for Jun 30, 2024, Doxa AB's PP&E Net amounts to 6.3m SEK.
What is Doxa AB's PP&E Net growth rate?
PP&E Net CAGR 10Y
51%
Over the last year, the PP&E Net growth was -24%. The average annual PP&E Net growth rates for Doxa AB have been 216% over the past three years , 99% over the past five years , and 51% over the past ten years .